Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:60901 |
Name | Waldenstroem's macroglobulinemia |
Definition | A lymphoplasmacytic lymphoma characterized by the accumulation of monoclonal cells in the bone marrow and peripheral lymphoid tissues, and associated with the production of serum immunoglobulin M (IgM) monoclonal protein. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma lymphoplasmacytic lymphoma Waldenstroem's macroglobulinemia |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02339922 | Phase II | Ixazomib + Rituximab | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | Active, not recruiting | USA | 0 |
NCT02457598 | Phase I | Entospletinib + Tirabrutinib Tirabrutinib Idelalisib + Obinutuzumab + Tirabrutinib Entospletinib + Obinutuzumab + Tirabrutinib Idelalisib + Tirabrutinib | Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies | Active, not recruiting | USA | FRA | 1 |
NCT02576496 | Phase I | Tinostamustine | Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | Recruiting | USA | ITA | FRA | ESP | DEU | 2 |
NCT03085173 | Phase I | EGFRt/19-28z/4-1BBL CAR T cells | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03147885 | Phase Ib/II | Selinexor | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | Recruiting | USA | 0 |
NCT03162536 | Phase I | ARQ 531 | Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03364231 | Phase II | Umbralisib | Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma | Completed | USA | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Recruiting | USA | 0 |
NCT03498612 | Phase II | Pembrolizumab | Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases | Active, not recruiting | USA | 0 |
NCT03557619 | Phase I | Ethinylestradiol + Levonorgestrel + Venetoclax | A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies | Recruiting | USA | 1 |
NCT03630042 | Phase II | Pembrolizumab + Rituximab | Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia (PembroWM) | Recruiting | 1 | |
NCT03711578 | Phase II | Tenalisib | Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K delta/gamma Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) | Completed | USA | 1 |
NCT03740529 | Phase Ib/II | Cyclophosphamide + Doxorubicin + Pirtobrutinib + Prednisone + Rituximab + Vincristine Sulfate Pirtobrutinib + Rituximab + Venetoclax Pirtobrutinib + Venetoclax Pirtobrutinib | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | Recruiting | USA | ITA | FRA | 7 |
NCT03779113 | Phase Ib/II | HMPL-523 | An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma | Recruiting | USA | ITA | ESP | 2 |
NCT03786926 | Phase Ib/II | HMPL-689 | Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas | Active, not recruiting | USA | ITA | FRA | ESP | 2 |
NCT03833180 | Phase I | VLS-101 | A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT03920631 | Phase I | Nivolumab | Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) | Withdrawn | USA | 0 |
NCT04052854 | Expanded access | Zanubrutinib | A Single-Arm, Expanded Access Study of Zanubrutinib (BGB3111) in Patients With B-cell Malignancies | No longer available | USA | 0 |
NCT04061512 | Phase II | Cyclophosphamide + Dexamethasone + Rituximab Ibrutinib + Rituximab | Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia (RAINBOW) | Recruiting | 1 | |
NCT04072458 | Phase I | BP1002 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | Recruiting | USA | 0 |
NCT04115059 | Phase I | Dasatinib | Dasatinib In Waldenstrom Macroglobulinemia | Recruiting | USA | 0 |
NCT04260217 | Phase I | APG-2575 | APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenstrom Macroglobulinemia (MAPLE-1) | Recruiting | USA | 2 |
NCT04273139 | Phase II | Ibrutinib + Venetoclax | Ibrutinib + Venetoclax in Untreated WM | Active, not recruiting | USA | 0 |
NCT04274738 | Phase I | Ibrutinib + X4P-001 | A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 | Completed | USA | 1 |
NCT04277637 | Phase I | BGB-11417 + Zanubrutinib BGB-11417 | Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | Recruiting | USA | ESP | 2 |
NCT04540796 | Phase I | JNJ-75348780 | A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | FRA | ESP | 7 |
NCT04624906 | Phase II | Acalabrutinib + Bendamustine + Rituximab | Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (BRAWM) | Recruiting | CAN | 0 |
NCT04635683 | Phase I | Lenalidomide + Ublituximab + Umbralisib | Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | Withdrawn | 0 | |
NCT04665115 | Phase II | Ibrutinib | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | Withdrawn | USA | 0 |
NCT04728893 | Phase II | ARQ 531 | Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies (MK-1026-003) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 10 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04775745 | Phase I | LP-168 | Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. | Recruiting | USA | 0 |
NCT04830137 | Phase I | NX-2127 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | USA | 0 |
NCT04840602 | Phase II | Ibrutinib + Rituximab + Venetoclax Ibrutinib + Rituximab | Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | Suspended | USA | 0 |
NCT04842877 | Phase II | DS-3201b | Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma | Recruiting | FRA | BEL | 0 |
NCT04861779 | Phase I | HSK29116 | A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | 2 | |
NCT05003141 | Phase I | PSB202 | PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies | Recruiting | USA | 2 |
NCT05006716 | Phase I | BGB-16673 | A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies | Recruiting | USA | 1 |
NCT05020678 | Phase I | Cyclophosphamide + Fludarabine NKX019 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | Recruiting | USA | 1 |
NCT05065554 | Phase II | Acalabrutinib + Rituximab | ACALA-R In Anti-MAG Neuropathy Mediated Neuropathy | Recruiting | USA | 0 |
NCT05131022 | Phase I | NX-5948 | Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Recruiting | 1 | |
NCT05172700 | Expanded access | Pirtobrutinib | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | Available | 0 | |
NCT05256641 | Phase Ib/II | Acalabrutinib | Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | Not yet recruiting | USA | 0 |
NCT05293912 | Phase I | SG2501 | SG2501 Safety Study in Subjects With Relapsed or Refractory Hematological Malignancies and Lymphoma. | Recruiting | USA | 0 |
NCT05424822 | Phase I | JNJ-80948543 | A Study of JNJ-80948543, a T Cell Redirecting Antibody, in Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) | Recruiting | USA | FRA | 4 |
NCT05537766 | Phase II | Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine | Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25) | Recruiting | USA | 0 |